Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_assertion type Assertion NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_head.
- NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.
- NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_assertion evidence source_evidence_literature NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.
- NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_assertion SIO_000772 21775097 NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.
- NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_assertion wasDerivedFrom befree-20150227 NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.
- NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_assertion wasGeneratedBy ECO_0000203 NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.